Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 5 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 426 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar gatorfanatic (52.17) Submitted: 9/4/2015 1:53:39 PM : Outperform Start Price: $101.88 GILD Score: -0.05

Strong pipeline and a big moat on several key areas for HIV and Hep C.

Recs

0
Member Avatar blake303 (29.20) Submitted: 8/31/2015 10:39:35 PM : Outperform Start Price: $25.68 GILD Score: +252.47

Dividend growth champion in the making

Recs

0
Member Avatar Johnwalsh99 (< 20) Submitted: 8/20/2015 3:12:08 PM : Outperform Start Price: $110.54 GILD Score: -3.13

Bought this stock earnings are solid and growth very good . GILD leads HIV industry and hepatitis C with new drug Harvoni making out standings margins and profit!!

Recs

0
Member Avatar optioncoach (91.02) Submitted: 8/18/2015 2:36:39 PM : Outperform Start Price: $117.14 GILD Score: -4.56

Putting some long biotech back in the portfolio.

Recs

0
Member Avatar LifeForceDancr (32.75) Submitted: 8/17/2015 8:21:00 PM : Outperform Start Price: $116.53 GILD Score: -4.00

Biotech

Recs

0
Member Avatar MiKull (48.97) Submitted: 8/16/2015 2:11:18 AM : Outperform Start Price: $115.08 GILD Score: -3.58

A solid stable of in demand pharma products, it knows how to effectively deal with the FDA due to successful products, and will use its research and process leverage to its advantage

Recs

0
Member Avatar 20for5 (42.95) Submitted: 8/11/2015 3:05:34 AM : Outperform Start Price: $115.12 GILD Score: -3.49

I'm watching a group of 20 stocks that are predominately priced at or below fair value based on historic valuations. The portfolio has an above average starting yield of about 3.35% compared to the S&P 500's 1.95%. The portfolio is designed to replicate something I might choose in retirement in order to live off of dividends alone instead of share harvesting and was inspired by a series of articles by Chuck Carnevale . My goal is to not make any changes for at least 5 years unless a dividend is frozen, cut or, I see a golden opportunity that increases current income as well as offers a better than average chance at capital appreciation. The portfolio doesn't need to necessarily beat the market for me to be satisfied with it's performance but I expect it to competitive in both short and longer time horizons as well as generate a rising income stream.

See ya in 2020.

Recs

0
Member Avatar Hopel3ss (87.04) Submitted: 8/10/2015 11:12:11 PM : Outperform Start Price: $115.12 GILD Score: -3.49

5-star CAPS pick. Also SA best buy now.

Recs

0
Member Avatar mcsprof (50.62) Submitted: 7/26/2015 10:19:27 PM : Outperform Start Price: $112.63 GILD Score: -2.44

Gilead is a well managed pharmaceutical company with several drugs with good prospects in the pipeline.

Recs

0
Member Avatar healthcarevalue (97.75) Submitted: 7/25/2015 9:23:48 PM : Outperform Start Price: $112.63 GILD Score: -2.44

Gilead Sciences Inc. (GILD) - debt/equity ratio of 0.69. Return on Invested Capital (ROIC) last TTM of 55.41 is quite impressive to say the least. TTM price/earnings ratio of 12.9 shows stock is priced cheaply compared to its industry at present. Lots of great niche healthcare products, as well as good strategic partnerships with other medical companies.

Recs

0
Member Avatar Orthonormal (90.42) Submitted: 7/25/2015 12:29:42 AM : Outperform Start Price: $112.63 GILD Score: -2.44

Magic Formula 12/12/2014

Recs

0
Member Avatar dmick9 (27.52) Submitted: 7/24/2015 10:45:16 AM : Outperform Start Price: $114.86 GILD Score: -3.09

Strong sales and growth in the HIV and hepatitis C markets along with a growing cash balance give Gilead both a strong case for both organic growth and growth through acquisitions and/or share buybacks & dividend hikes.

Recs

0
Member Avatar bullishsky (< 20) Submitted: 7/16/2015 11:01:12 AM : Outperform Start Price: $118.78 GILD Score: -4.97

Pharma success with great opportunity

Recs

0
Member Avatar xdmarz (< 20) Submitted: 7/15/2015 8:01:52 PM : Outperform Start Price: $118.33 GILD Score: -4.64

Pharmacuticals, Yeah!!

Recs

0
Member Avatar wstanislaw (33.52) Submitted: 7/10/2015 5:59:12 PM : Outperform Start Price: $114.66 GILD Score: -3.02

Eps of $8.80 at 13% growth easily supports the current share price. Potentials for this company are enormous with their hepatitis, hiv and cancer treatments, plus the global markets are opening for them as well.

Recs

1
Member Avatar TMFCheesehead (59.87) Submitted: 7/10/2015 4:19:54 PM : Outperform Start Price: $115.00 GILD Score: -3.39

It's hard to argue against a company with this valuation and such a huge pile of cash.

Recs

0
Member Avatar bcurtis9944 (41.72) Submitted: 7/7/2015 11:15:33 PM : Outperform Start Price: $114.25 GILD Score: -3.24

one third the p/e of its direct competitor ABBV.
Japan just approved the new hepatitis drug,
Japan has the highest rates of liver diseases

Recs

0
Member Avatar haledrich (< 20) Submitted: 6/24/2015 11:35:49 PM : Outperform Start Price: $122.48 GILD Score: -7.89

great pipeline

Recs

0
Member Avatar DrGoldin (99.70) Submitted: 6/24/2015 11:00:21 AM : Outperform Start Price: $49.32 GILD Score: +86.03

With the share price at an all-time high and most of the earnings growth behind us, I'm trimming my real position in Gilead (cha-ching!), but in CAPS I can't afford to do that, because the peculiar rules of the game make it advantageous to keep the position open when you have a low start price.

(My favorite big-boy biotech right now is Celgene. It's my biggest single holding.)

Recs

0
Member Avatar clangmead (36.08) Submitted: 6/23/2015 7:50:36 AM : Outperform Start Price: $121.82 GILD Score: -6.99

posh

Featured Broker Partners